The side effects of ACEIs and ARBs may be resulting in less frequent use in a population that could benefit from these medications. A new study found that continuous ACEI/ARB use prior to dialysis ...

High blood pressure and cardiovascular and renal diseases are often treated with a combination of renin-angiotensin-aldosterone system inhibitors. However, as these agents have the potential to cause ...

In patients with type 2 diabetes (T2D), the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and sustained use of guideline-recommended renin ...

WASHINGTON—Patients with chronic kidney disease (CKD) who discontinue treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) following an episode of ...

Many prescribers discontinue patients' angiotension-converting enzyme inhibitors (ACE-Is) or angiotension receptor blockers (ARBs) as their estimated glomerular filtration rate (eGFR) worsens due to ...

A new risk model may help identify which patients with chronic kidney disease (CKD) and diabetes are more likely to develop hyperkalemia, granting physicians more confidence in prescribing medications ...

ARB stands for Angiotensin II Receptor Blocker, a type of medication primarily used to treat high blood pressure. How do ARBs ...

Among the drug combinations that may increase serum potassium in patients with diabetic kidney disease, those that include a mineralocorticoid receptor antagonist (MRA) carry the highest risk for ...

Credit: Getty Images. The risk for hyperkalemia was highest with use of steroidal MRAs in combination with other RAASi. In patients with diabetic kidney disease, use of 2 classes of ...

Are there clinical advantages to augmenting standard therapy for stable ischemic heart disease with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)? Adding an ...